Danaher sees slowing topline growth as pandemic impact wanes (NYSE:DHR)

Rolled newspaper with the headline Quarterly Results

Zerbor/iStock via Getty Images

Despite reporting better than expected Q4 2022 financials, COVID-19 test maker Danaher Corporation (NYSE:DHR) indicated a slowdown in topline growth Tuesday as the pandemic impact waned.

The Washington, DC-based life sciences company posted ~$8.4B in revenue for thepast twelve months.

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!